Chinook Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Eric L. Dobmeier
- Full Time Employees
- 214
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 400 Fairview Avenue North Seattle WA United States of America 98109
- IPO Date
- Oct 6, 2020
- CIK
- 0001435049
- Website
- chinooktx.com
- Similar Companies
- Business
- Chinook Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases, operates as a wholly-owned subsidiary of Novartis AG following its acquisition in August 2023 for $3.2 billion upfront plus up to $300 million in contingent value rights; the company, founded in 2019 and headquartered in Seattle, Washington, with additional facilities in Vancouver, Canada, and Oakland, California, advances a pipeline targeting proteinuric glomerular diseases and other renal disorders primarily in North America and globally through Novartis. Its lead product candidate, atrasentan (marketed by Novartis as Vanrafia), is an oral, selective endothelin A receptor antagonist in Phase III development for immunoglobulin A nephropathy (IgAN) and other proteinuric diseases, demonstrating significant proteinuria reductions in clinical trials and receiving U.S. FDA accelerated approval in April 2025; zigakibart (formerly BION-1301), a subcutaneously administered anti-APRIL monoclonal antibody, advances in Phase III for IgAN with topline data expected in 2026 and regulatory submission planned for 2027 or later; earlier-stage assets include CHK-336, an oral small molecule lactate dehydrogenase A inhibitor for primary hyperoxaluria in Phase I, alongside research programs leveraging single-cell RNA sequencing, organoids and translational models for additional kidney diseases. Recent milestones encompass the Novartis acquisition completion, which expanded the renal portfolio with complementary assets like iptacopan (Fabhalta); FDA accelerated approval of atrasentan/Vanrafia fulfilling a key contingent value right milestone in 2025; and ongoing Phase III readouts for atrasentan reported in 2024 confirming clinical benefits in IgAN, positioning the programs as potential foundational therapies for underserved patients with persistent proteinuria and progressive kidney decline.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
Novartis Completes Acquisition of Chinook Therapeutics
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
Chief Scientific Officer Andrew King Sells 1,168 Shares of Chinook Therapeutics Inc (KDNY)
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
CHINOOK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chinook Therapeutics, Inc. - KDNY
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc. - KDNY
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc. - KDNY
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm